- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT03787121
Estimation of Economic Consequences Linked With Different Care Management Pathways of Differentiated Thyroid Cancers (ECO-THYR)
Estimation of Economic Consequences Linked With Different Care Management Pathways of Differentiated Thyroid Cancers : Involvement of Overtreatment
The incidence of Thyroid Cancer (TC) has increased over the last thirty years, in France and worldwide. This increase is mainly due to good prognosis microPapillary TC (mPTC). Sixty percent of diagnosed cancers are considered as over-diagnosed, leading to an over-treatment of these cases. The increase of diagnosis of mPTC and its treatment inevitably leads to an increase of medical resources consumption and corresponding costs.
The primary aim of this study is to estimate the cost related to different care management pathway of TC patient during a lifetime period using a multi-state Markov model.
This is a retrospective, observational population based cohort study, using data from a cohort study of TC patients implemented by the ONCOMIP network which initially aimed to perform an audit of clinical practices for the management of TC, and from database of the French social health insurance of Midi-Pyrenees region to calculate observed costs of TC management during 24 months.
Study Overview
Status
Conditions
Intervention / Treatment
Study Type
Enrollment (Actual)
Contacts and Locations
Study Locations
-
-
-
Toulouse, France
- University HospitalToulouse
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Sampling Method
Study Population
Description
Inclusion Criteria:
- all patients with a good prognosis of the TC
- diagnosed in 2014
- whose medical file discussed in MultiDisciplinary Team Meeting (MDTM) in Midi-Pyrenees
Exclusion Criteria:
- patients whose surgical management was carried out outside Midi Pyrenees are excluded and other morphological types are excluded (medullar, anaplastic, lymphomas, sarcomas)
Study Plan
How is the study designed?
Design Details
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
cost related to the different management pathways of TC patient
Time Frame: 24 months
|
estimate the cost related to the different management pathways of TC patient during a lifetime period using a multi-state Markov model
|
24 months
|
Collaborators and Investigators
Sponsor
Investigators
- Principal Investigator: Nadège Costa, PhD, University Hospital, Toulouse
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- RC31/17/0378
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Thyroid Cancer
-
National Cancer Institute (NCI)TerminatedInsular Thyroid Cancer | Recurrent Thyroid Cancer | Stage IV Follicular Thyroid Cancer | Stage IV Papillary Thyroid Cancer | Anaplastic Thyroid Cancer | Stage III Follicular Thyroid Cancer | Stage III Papillary Thyroid CancerUnited States
-
National Cancer Institute (NCI)CompletedRecurrent Thyroid Cancer | Stage IVA Follicular Thyroid Cancer | Stage IVA Papillary Thyroid Cancer | Stage IVB Follicular Thyroid Cancer | Stage IVB Papillary Thyroid Cancer | Stage IVC Follicular Thyroid Cancer | Stage IVC Papillary Thyroid CancerUnited States
-
University of WashingtonNational Cancer Institute (NCI); GlaxoSmithKline; National Comprehensive Cancer...CompletedRecurrent Thyroid Cancer | Stage IVA Follicular Thyroid Cancer | Stage IVA Papillary Thyroid Cancer | Stage IVB Follicular Thyroid Cancer | Stage IVB Papillary Thyroid Cancer | Stage IVC Follicular Thyroid Cancer | Stage IVC Papillary Thyroid CancerUnited States
-
University of PennsylvaniaCompletedMetastatic Medullary Thyroid Cancer | Metastatic Differentiated Thyroid Cancer | Metastatic Anaplastic Thyroid Cancer | Metastatic Poorly Differentiated Thyroid CancerUnited States
-
Children's Hospital of PhiladelphiaEli Lilly and Company; United States Department of DefenseRecruitingCancer | Pediatric Cancer | Differentiated Thyroid Cancer | Cancer, ThyroidUnited States
-
National Cancer Institute (NCI)CompletedInsular Thyroid Cancer | Recurrent Thyroid Cancer | Stage II Follicular Thyroid Cancer | Stage II Papillary Thyroid Cancer | Stage IV Follicular Thyroid Cancer | Stage IV Papillary Thyroid CancerUnited States
-
Children's Hospital of PhiladelphiaBayerRecruitingCancer | Pediatric Cancer | Differentiated Thyroid Cancer | Cancer, ThyroidUnited States
-
H. Lee Moffitt Cancer Center and Research InstituteTerminatedThyroid Cancer, Medullary | Thyroid Cancer | Papillary Thyroid Cancer | Differentiated Thyroid Cancer | Poorly Differentiated Thyroid Gland Carcinoma | Follicular Thyroid CancerUnited States
-
National Cancer Institute (NCI)CompletedRecurrent Thyroid Cancer | Stage IV Follicular Thyroid Cancer | Stage IV Papillary Thyroid CancerUnited States
-
Memorial Sloan Kettering Cancer CenterActive, not recruitingThyroid Cancer, Follicular | Thyroid Cancer | Papillary Thyroid Cancer | Poorly Differentiated Thyroid Gland Carcinoma | Follicular Thyroid Cancer | Hurthle Cell Tumor | Hurthle Cell Thyroid NeoplasiaUnited States
Clinical Trials on care management pathways
-
Massachusetts General HospitalUnited States Department of DefenseRecruitingPDAC - Pancreatic Ductal AdenocarcinomaUnited States
-
Laurie McLouthNational Cancer Institute (NCI)Recruiting
-
Duke UniversityRecruitingDiagnostic Imaging | Cardiac Tamponade | Implementation Science | Pericardial Effusion | Heart Failure Acute | Medical Training | Pulmonary Embolism (Diagnosis) | Point of Care Ultrasound (POCUS) | Cardiovascular Disease Acute | Emergency Department PatientUnited States
-
Massachusetts General HospitalRecruitingRectal Cancer | Self EfficacyUnited States
-
Agenzia Regionale Sanitaria delle MarcheCompleted
-
Oslo University HospitalNorwegian University of Science and TechnologyCompleted
-
University Hospital, ToulouseCompleted
-
University of AarhusAarhus University HospitalCompleted
-
University of British ColumbiaCanadian Institutes of Health Research (CIHR)CompletedFemoral Fractures | Hip FracturesCanada
-
European Pathway AssociationKU LeuvenCompleted